EGFR and non-small cell lung carcinoma: Between February 25, 2022, and April 29, 2024, a total of 182 patients with locally advanced or metastatic NSCLC harboring EGFR Ex19del/L858R mutation at the first-line treatment failure of osimertinib were prospectively enrolled.